(MRK) Merck - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US58933Y1055
Stock:
Total Rating 61
Risk 56
Buy Signal 0.44
| Risk 5d forecast | |
|---|---|
| Volatility | 27.3% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 24.00 |
| Character TTM | |
|---|---|
| Beta | 0.550 |
| Beta Downside | 0.449 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.44% |
| CAGR/Max DD | 0.16 |
EPS (Earnings per Share)
Revenue
Description: MRK Merck
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 18.25b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -7.32 > 1.0 |
| NWC/Revenue: 29.12% < 20% (prev 16.15%; Δ 12.97% < -1%) |
| CFO/TA 0.11 > 3% & CFO 13.62b > Net Income 18.25b |
| Net Debt (-18.21b) to EBITDA (28.80b): -0.63 < 3 |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.49b) vs 12m ago -2.09% < -2% |
| Gross Margin: 81.50% > 18% (prev 0.76%; Δ 8074 % > 0.5%) |
| Asset Turnover: 52.71% > 50% (prev 54.79%; Δ -2.08% > 0%) |
| Interest Coverage Ratio: 25.93 > 6 (EBITDA TTM 28.80b / Interest Expense TTM 945.0m) |
Altman Z'' 4.81
| A: 0.15 (Total Current Assets 47.56b - Total Current Liabilities 28.63b) / Total Assets 129.55b |
| B: 0.56 (Retained Earnings 72.23b / Total Assets 129.55b) |
| C: 0.20 (EBIT TTM 24.50b / Avg Total Assets 123.33b) |
| D: 0.67 (Book Value of Equity 51.85b / Total Liabilities 77.64b) |
| Altman-Z'' Score: 4.81 = AA |
Beneish M
| DSRI: none (Receivables none/10.28b, Revenue 65.01b/64.17b) |
| GMI: 0.94 (GM 81.50% / 76.32%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.01 (Revenue 65.01b / 64.17b) |
| TATA: 0.04 (NI 18.25b - CFO 13.62b) / TA 129.55b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of MRK shares?
As of February 27, 2026, the stock is trading at USD 119.30 with a total of 10,326,557 shares traded.
Over the past week, the price has changed by -2.10%, over one month by +11.08%, over three months by +15.00% and over the past year by +38.49%.
Over the past week, the price has changed by -2.10%, over one month by +11.08%, over three months by +15.00% and over the past year by +38.49%.
Is MRK a buy, sell or hold?
Merck has received a consensus analysts rating of 4.04.
Therefore, it is recommended to buy MRK.
- StrongBuy: 12
- Buy: 3
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 125.4 | 5.1% |
| Analysts Target Price | 125.4 | 5.1% |
MRK Fundamental Data Overview February 21, 2026
P/E Trailing = 16.739
P/E Forward = 9.1324
P/S = 4.682
P/B = 5.8334
P/EG = 0.8012
Revenue TTM = 65.01b USD
EBIT TTM = 24.50b USD
EBITDA TTM = 28.80b USD
Long Term Debt = 39.97b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.41b USD (from shortTermDebt, two quarters ago)
Debt = 41.37b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -18.21b USD (from netDebt column, last quarter)
Enterprise Value = 327.54b USD (304.38b + Debt 41.37b - CCE 18.21b)
Interest Coverage Ratio = 25.93 (Ebit TTM 24.50b / Interest Expense TTM 945.0m)
EV/FCF = 31.09x (Enterprise Value 327.54b / FCF TTM 10.54b)
FCF Yield = 3.22% (FCF TTM 10.54b / Enterprise Value 327.54b)
FCF Margin = 16.21% (FCF TTM 10.54b / Revenue TTM 65.01b)
Net Margin = 28.08% (Net Income TTM 18.25b / Revenue TTM 65.01b)
Gross Margin = 81.50% ((Revenue TTM 65.01b - Cost of Revenue TTM 12.03b) / Revenue TTM)
Gross Margin QoQ = 92.71% (prev 77.69%)
Tobins Q-Ratio = 2.53 (Enterprise Value 327.54b / Total Assets 129.55b)
Interest Expense / Debt = 0.79% (Interest Expense 327.0m / Debt 41.37b)
Taxrate = 13.39% (458.0m / 3.42b)
NOPAT = 21.22b (EBIT 24.50b * (1 - 13.39%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.91b)
Debt / EBITDA = -0.63 (Net Debt -18.21b / EBITDA 28.80b)
Debt / FCF = -1.73 (Net Debt -18.21b / FCF TTM 10.54b)
Total Stockholder Equity = 50.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.80% (Net Income 18.25b / Total Assets 129.55b)
RoE = 36.31% (Net Income TTM 18.25b / Total Stockholder Equity 50.27b)
RoCE = 27.15% (EBIT 24.50b / Capital Employed (Equity 50.27b + L.T.Debt 39.97b))
RoIC = 24.41% (NOPAT 21.22b / Invested Capital 86.93b)
WACC = 7.07% (E(304.38b)/V(345.75b) * Re(7.94%) + D(41.37b)/V(345.75b) * Rd(0.79%) * (1-Tc(0.13)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.30%
[DCF] Terminal Value 82.19% ; FCFF base≈13.56b ; Y1≈14.19b ; Y5≈16.46b
[DCF] Fair Price = 148.7 (EV 350.94b - Net Debt -18.21b = Equity 369.16b / Shares 2.48b; r=7.07% [WACC]; 5y FCF grow 5.00% → 2.90% )
EPS Correlation: 20.65 | EPS CAGR: -1.27% | SUE: 0.42 | # QB: 0
Revenue Correlation: 65.66 | Revenue CAGR: 0.83% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-1.46 | Chg7d=-0.012 | Chg30d=-0.678 | Revisions Net=+0 | Analysts=17
EPS current Year (2026-12-31): EPS=5.14 | Chg7d=+0.000 | Chg30d=-1.120 | Revisions Net=-8 | Growth EPS=-42.7% | Growth Revenue=+2.6%
EPS next Year (2027-12-31): EPS=9.78 | Chg7d=+0.029 | Chg30d=-0.180 | Revisions Net=-6 | Growth EPS=+90.1% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.0% (Discount Rate 7.9% - Earnings Yield 6.0%)
[Growth] Growth Spread = +0.5% (Analyst 2.5% - Implied 2.0%)
P/E Forward = 9.1324
P/S = 4.682
P/B = 5.8334
P/EG = 0.8012
Revenue TTM = 65.01b USD
EBIT TTM = 24.50b USD
EBITDA TTM = 28.80b USD
Long Term Debt = 39.97b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.41b USD (from shortTermDebt, two quarters ago)
Debt = 41.37b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -18.21b USD (from netDebt column, last quarter)
Enterprise Value = 327.54b USD (304.38b + Debt 41.37b - CCE 18.21b)
Interest Coverage Ratio = 25.93 (Ebit TTM 24.50b / Interest Expense TTM 945.0m)
EV/FCF = 31.09x (Enterprise Value 327.54b / FCF TTM 10.54b)
FCF Yield = 3.22% (FCF TTM 10.54b / Enterprise Value 327.54b)
FCF Margin = 16.21% (FCF TTM 10.54b / Revenue TTM 65.01b)
Net Margin = 28.08% (Net Income TTM 18.25b / Revenue TTM 65.01b)
Gross Margin = 81.50% ((Revenue TTM 65.01b - Cost of Revenue TTM 12.03b) / Revenue TTM)
Gross Margin QoQ = 92.71% (prev 77.69%)
Tobins Q-Ratio = 2.53 (Enterprise Value 327.54b / Total Assets 129.55b)
Interest Expense / Debt = 0.79% (Interest Expense 327.0m / Debt 41.37b)
Taxrate = 13.39% (458.0m / 3.42b)
NOPAT = 21.22b (EBIT 24.50b * (1 - 13.39%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.91b)
Debt / EBITDA = -0.63 (Net Debt -18.21b / EBITDA 28.80b)
Debt / FCF = -1.73 (Net Debt -18.21b / FCF TTM 10.54b)
Total Stockholder Equity = 50.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.80% (Net Income 18.25b / Total Assets 129.55b)
RoE = 36.31% (Net Income TTM 18.25b / Total Stockholder Equity 50.27b)
RoCE = 27.15% (EBIT 24.50b / Capital Employed (Equity 50.27b + L.T.Debt 39.97b))
RoIC = 24.41% (NOPAT 21.22b / Invested Capital 86.93b)
WACC = 7.07% (E(304.38b)/V(345.75b) * Re(7.94%) + D(41.37b)/V(345.75b) * Rd(0.79%) * (1-Tc(0.13)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.30%
[DCF] Terminal Value 82.19% ; FCFF base≈13.56b ; Y1≈14.19b ; Y5≈16.46b
[DCF] Fair Price = 148.7 (EV 350.94b - Net Debt -18.21b = Equity 369.16b / Shares 2.48b; r=7.07% [WACC]; 5y FCF grow 5.00% → 2.90% )
EPS Correlation: 20.65 | EPS CAGR: -1.27% | SUE: 0.42 | # QB: 0
Revenue Correlation: 65.66 | Revenue CAGR: 0.83% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-1.46 | Chg7d=-0.012 | Chg30d=-0.678 | Revisions Net=+0 | Analysts=17
EPS current Year (2026-12-31): EPS=5.14 | Chg7d=+0.000 | Chg30d=-1.120 | Revisions Net=-8 | Growth EPS=-42.7% | Growth Revenue=+2.6%
EPS next Year (2027-12-31): EPS=9.78 | Chg7d=+0.029 | Chg30d=-0.180 | Revisions Net=-6 | Growth EPS=+90.1% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.0% (Discount Rate 7.9% - Earnings Yield 6.0%)
[Growth] Growth Spread = +0.5% (Analyst 2.5% - Implied 2.0%)